InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R)...

InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of
Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early

OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today
that it has been engaged by InDex Pharmaceuticals AB to advise and assist in
out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the
treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD).
The engagement will utilise PharmaVentures' transactions experience in the
healthcare and investment business sectors.

Kappaproct, approved for Orphan Drug Designation in Europe, has recently
successfully concluded its third clinical phase II trial for the treatment of
Inflammatory Bowel Disease patients. Due to the highly positive interim
results at both one and four weeks after dosing, this trial, which included 34
patients and was conducted as a multi-center study in Sweden and Russia, was
concluded early. Kappaproct showed the same excellent safety profile as seen
in previous trials.

Kappaproct is currently approved for clinical developmental use as a rectal,
single-dose administration. Qualification of the compound for other routes of
administration and multiple dosing is underway through an extended toxicology
program.

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very
pleased to be involved in bringing this groundbreaking technology to the
market. InDex are leaders in the field of immunomodulation via Toll Like
Receptors."

InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also
InDex's Press Release released today:
http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf

Visit PharmaVentures during BIO at booths 4209 & 4211 for further information
on this and other licensing opportunities.

For enquiries about this opportunity, please contact:
Dr Adrian Dawkes
Managing Consultant
PharmaVentures
adrian.dawkes@pharmaventures.com
+44 (0) 1865 784 193

Notes to Editors:

A leading results driven organisation, PharmaVentures (www.pharmaventures.com)
assists pharmaceutical and biotechnology companies across the world in all
aspects of deal making. The Company's core business is the provision of
tailored consulting and transaction advisory services to the Life Science
industry, with additional deal making support provided through the PharmaDeals
range of intelligence products which include analysis tools and reports.

For further information please contact:
Fiona Bishop
PharmaVentures
+44 (0) 1865 784 187
fiona.bishop@pharmaventures.com

InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical
company building a leading immunotherapy franchise based on its DIMS platform
(DNA-based immunomodulatory sequence). DIMS drugs are developed to treat
diseases within a variety of therapeutic areas, including inflammation and
cancer. InDex has several proprietary DIMS compounds in various stages of
development, including Kappaproct, for the treatment of steroid
resistant/dependent ulcerative colitis.

Svante Rasmuson, CEO
Phone: +46 (0)8 50 88 47 31
Mobile: +46 (0)708 63 93 31
E-Mail: svante.rasmuson@indexpharmab.com

Oliver von Stein, CSO
Phone: +46 (0)8 50 88 47 32
Mobile: +46 (0)708 93 33 75
E-Mail: oliver.stein@indexpharmab.com

www.indexpharmab.com

SOURCE PharmaVentures

Dr Adrian Dawkes, Managing Consultant, +44(0)1865-784-193,
adrian.dawkes@pharmaventures.com, or Fiona Bishop, +44(0)1865-784-187,
fiona.bishop@pharmaventures.com, both of PharmaVentures; or Svante Rasmuson,
CEO, +46(0)8-50-88-47-31, Mobile, +46(0)708-63-93-31,
svante.rasmuson@indexpharmab.com, or Oliver von Stein, CSO,
+46(0)8-50-88-47-32, Mobile, +46(0)708-93-33-75,
oliver.stein@indexpharmab.com, both of InDex Pharmaceuticals